Mesa Laboratories (MLAB)
(Delayed Data from NSDQ)
$104.47 USD
-2.15 (-2.02%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $103.99 -0.48 (-0.46%) 7:58 PM ET
1-Strong Buy of 5 1
C Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for Mesa Laboratories, Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | NA | 219 | 184 | 134 | 118 |
Cost Of Goods | NA | 85 | 75 | 47 | 53 |
Gross Profit | NA | 134 | 109 | 87 | 65 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 130 | 104 | 75 | 57 |
Income After Depreciation & Amortization | 0 | 3 | 5 | 12 | 7 |
Non-Operating Income | NA | 1 | 3 | -2 | 1 |
Interest Expense | NA | 5 | 4 | 8 | 6 |
Pretax Income | NA | 0 | 4 | 2 | 3 |
Income Taxes | NA | -1 | 2 | -1 | 2 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | 1 | 2 | 3 | 1 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | 1 | 2 | 3 | 1 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | 37 | 37 | 35 | 33 |
Depreciation & Amortization (Cash Flow) | NA | 34 | 33 | 23 | 25 |
Income After Depreciation & Amortization | 0 | 3 | 5 | 12 | 7 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | NA | 5.36 | 5.34 | 5.12 | 4.37 |
Diluted EPS Before Non-Recurring Items | NA | 5.55 | 4.96 | 5.24 | 4.21 |
Diluted Net EPS (GAAP) | NA | 0.17 | 0.35 | 0.64 | 0.31 |
Fiscal Year end for Mesa Laboratories, Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 53.47 | 53.17 | 50.65 | 55.59 |
Cost Of Goods | NA | 20.07 | 21.06 | 19.46 | 22.39 |
Gross Profit | NA | 33.40 | 32.11 | 31.18 | 33.20 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 33.47 | 32.17 | 31.85 | 32.68 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -0.07 | -0.06 | -0.67 | 0.52 |
Non-Operating Income | NA | 3.87 | -0.36 | 0.78 | 0.59 |
Interest Expense | NA | 1.86 | 0.91 | 1.05 | 1.38 |
Pretax Income | NA | 1.95 | -1.33 | -0.94 | -0.28 |
Income Taxes | NA | -0.17 | -0.10 | -0.39 | -0.89 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 2.12 | -1.23 | -0.55 | 0.61 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 2.12 | -1.23 | -0.55 | 0.61 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 5.40 | 5.39 | 5.37 | 5.38 |
Diluted EPS Before Non-Recurring Items | NA | 1.46 | 1.32 | 1.22 | 1.46 |
Diluted Net EPS (GAAP) | NA | 0.39 | -0.23 | -0.10 | 0.12 |